Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses

Xuanming Yang, Xunmin Zhang, May Lynne Fu, Ralph R. Weichselbaum, Thomas F. Gajewski, Yajun Guo, Yang Xin Fu

Research output: Contribution to journalArticle

135 Scopus citations


Antibodies (Abs) that preferentially target oncogenic receptors have been increasingly used for cancer therapy, but tumors often acquire intrinsic Ab resistance after prolonged and costly treatment. Herein we armed the Ab with IFNβ and observed that it is more potent than the first generation of Ab for controlling Ab-resistant tumors. This strategy controls Ab resistance by rebridging suppressed innate and adaptive immunity in the tumor microenvironment. Mechanistically, Ab-IFNβ therapy primarily and directly targets intratumoral dendritic cells, which reactivate CTL by increasing antigen cross-presentation within the tumor microenvironment. Additionally, blocking PD-L1, which is induced by Ab-IFNβ treatment, overcomes treatment-acquired resistance and completely eradicates established tumors. This study establishes a next-generation Ab-based immunotherapy that targets and eradicates established Ab-resistant tumors.

Original languageEnglish (US)
Pages (from-to)37-48
Number of pages12
JournalCancer Cell
Issue number1
StatePublished - Jan 13 2014


ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this